Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

'Sharing' Organizations Stay In Final Post-Market Cybersecurity Guidance

Executive Summary

Despite pushback from industry groups on the use of information-sharing and analysis organizations (ISAOs), US FDA has kept the language the same in its final post-market cybersecurity guidance, but has removed the term "essential clinical performance."

You may also be interested in...



US, Canada Setting Trend For Global Cybersecurity Guidance

A draft IMDRF guidance released this month aims to set the trend for how regulators around the world oversee cybersecurity of medical devices. According to experts, the document also foreshadows what sponsors can expect from the US FDA in areas such as developing a software bill of materials, as the agency updates its own cybersecurity guidances.

Cybersecurity Vulnerability Could Seriously Impact Wide Range Of Medtech Industry, FDA Warns

The US agency issued a safety communication on 1 October warning manufacturers, providers and patients of 11 serious exploits on a wide range of connected medical devices that could allow malicious hackers to not just steal patient data, but harm patients by altering how the devices function.

Compliance Corner: When Is An Action Exempt From FDA's Recall Reporting Requirements?

Two longtime industry experts break down the US FDA’s rules around when an action becomes reportable as a recall to the agency. The bottom line: If you’re changing a device’s safety, then you should probably report it.

Related Content

Topics

UsernamePublicRestriction

Register

OM002409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel